AKT1 and neuroblastoma: The AKT inhibitor perifosine has been tested in multiple phase I clinical trials, with 1 complete response and 8 of 27 children with relapsed neuroblastoma demonstrating prolonged stable disease in one phase I study [76], and response rates and disease control rates of 9% and 55% in 11 children with neuroblastoma with measurable disease [77].